Clinical Trial Update: ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI [Phase 2]

View source ↗

Summary

Phase 2 ICON-2 trial comparing fecal microbiota transplantation plus bezlotoxumab versus fecal microbiota transplantation plus placebo in patients with inflamma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection
• Inflammatory Bowel Disease

Drugs mentioned

• Zinplava (bezlotoxumab) (bezlotoxumab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Inflammatory Bowel Diseases, Clostridium Difficile Infection | Phase 2 | Status: COMPLETED | Results posted: 2024-12-11